Cardinal Health, Inc.’s stock price dips to $112.51, marking a 1.17% decline

Cardinal Health, Inc. (CAH)

112.51 USD -1.33 (-1.17%) Volume: 1.91M

Cardinal Health, Inc.’s stock price currently stands at 112.51 USD, experiencing a slight dip of -1.17% this trading session, with a trading volume of 1.91M. Despite the day’s drop, CAH’s stock showcases a robust performance with a year-to-date increase of +11.62%, indicating a promising investment opportunity.

Latest developments on Cardinal Health, Inc.

Investors are closely monitoring Cardinal Health (NYSE: CAH) as the company’s stock price movements have been influenced by key events recently. The Cardinal Health Foundation, in collaboration with the NCPA, has been offering mental health tools for pharmacies, which has been positively received by the market. Additionally, Cardinal Health and NCPA have teamed up to expand mental health resources for pharmacists, further boosting investor confidence. Pensionfund Sabic and Tobam have also made significant investments in Cardinal Health, with the former investing $1.11 million and the latter holding a $3.11 million position in the company. Furthermore, Cardinal Health recently filed an 8-K disclosing unregistered sales of equity securities, indicating strategic financial moves. Despite a downgrade by StockNews.com to Buy, options for Cardinal Health are now available as of November 29th, suggesting potential volatility in the stock price.

Cardinal Health, Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma have provided bullish coverage on Cardinal Health Inc., highlighting the company’s strong operational performance and significant improvement in key financial metrics. In their research report titled “Cardinal Health Inc.: How Are They Achieving Specialty Business Growth Despite Nonrenewal Challenges! – Major Drivers,” the analysts noted a remarkable year for Cardinal Health, with a 29% increase in earnings per share (EPS) for the entire fiscal year 2024. This positive trajectory, exceeding the company’s initial guidance, indicates a promising outlook for Cardinal Health.

Furthermore, Baptista Research‘s analysts also published a bullish report on Cardinal Health, emphasizing the company’s deep-rooted market relationships and competitive edge. In their report titled “Cardinal Health: Deep-Rooted Market Relationships & Competitive Edge! – Major Drivers,” the analysts highlighted the company’s strong performance in Q3 FY2024, driven by growth in the pharmaceutical and specialty solutions business. Cardinal Health‘s focus on its strategic priorities has led to broad-based growth and raised outlook for the fiscal year ’24, showcasing its resilience in the healthcare products and services sector.

A look at Cardinal Health, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Cardinal Health‘s long-term outlook appears promising, as indicated by its Smart Scores. With high scores in Dividend, Growth, Resilience, and Momentum, the company seems well-positioned for future success. Cardinal Health provides a range of products and services to healthcare providers and manufacturers, including pharmaceutical distribution, health-care product manufacturing, and consulting services. This diverse portfolio of offerings suggests a strong foundation for continued growth and stability in the industry.

Overall, Cardinal Health‘s Smart Scores paint a positive picture for the company’s future prospects. With a focus on value, dividend, growth, resilience, and momentum, Cardinal Health appears to be on a solid path for long-term success. The company’s commitment to providing essential products and services to the healthcare industry positions it well for sustained growth and profitability in the years to come.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma